The long saga of Teva Pharmaceuticals USA Inc.’s fight to block additional Copaxone competitors from entering the market appears to have come to an end with a district court ruling that the US Food and Drug Administration reasonably determined that the multiple sclerosis treatment is not a biologic.
Teva filed suit against FDA last year challenging its decision to exclude Copaxone (glatiramer acetate injection) from a list of...